Next Generation Sequencing (NGS) Prep Kits to be Distributed in the U.S. by AdvancedDx Biological Laboratories USA Inc. and Medline Industries, LP

Newburyport, MA, USA – AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD), a company listed on the Euronext stock exchange, has announced the signing of a non-exclusive distribution agreement with Medline Industries, LP ( The agreement grants Medline the rights to promote and commercialize ABLD’s Next Generation Sequencing (NGS) solutions, including new high-throughput library preparation kits, in the United States.

According to market research, the NGS market was valued at USD 1.42 billion in 2022 and is expected to continue growing at a compound annual growth rate (CAGR) of 13.16% from 2023 to 2030. ABLD’s NGS kits offer laboratories and centers involved in NGS sequencing an efficient and scalable solution that decreases workflow time compared to other methodologies.

The NGS kits have been designed for optimal efficiency, with a turnaround time of approximately 75 minutes for the entire library preparation workflow. They also boast robustness, high-quality DNA libraries, and dual indexing, making them compatible with all Illumina NGS systems (NextSeq, MiSeq, MiniSeq, iSeq-100…). This versatility allows for streamlined preparation and pooling of libraries for a wide range of samples and species.

Nicole Krpan, Medline Laboratories Division General Manager, expressed excitement about the distribution agreement, stating, “We are excited to begin distributing the ABL Diagnostics kits in the U.S., which will enable Medline to continue expanding our portfolio of offerings and bring efficiency to laboratories and genomic centers involved in NGS sequencing.”

Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics, added, “These NGS Kits help eliminate bottlenecks related to cost, time, and labor, making them one of the most cost-effective high-throughput library preparation solutions on the market. We are glad to develop this activity in the U.S. through Medline.”

The specific terms of the agreement have not been disclosed.


AdvancedDx Biological Laboratories USA Inc. is an affiliate of ABL Diagnostics S.A. (ABLD), a global leader in molecular biology assays for genotyping through DNA sequencing – DeepChek®. ABL Diagnostics is a publicly traded company listed on the Euronext stock exchange in Paris (Euronext: ABLD – ISIN: FR001400AHX6).

The company’s molecular biology products generate recurring revenue and cover one of the largest portfolios of microbiology applications. ABL Diagnostics distributes its products globally through its own sales team and a network of exclusive distributors on all continents. The company’s clients include academic laboratories, private laboratories, and researchers seeking to implement innovative and robust microbiology solutions.


Medline is a healthcare company that manufactures, distributes, and provides solutions to improve the overall operating performance of healthcare providers. With a focus on partnering across the continuum of care, Medline helps providers activate the clinical and supply chain resources needed to deliver the best care. With agility and scale, Medline invests in its customers for the future and rapidly responds to a dynamically changing market with customized solutions. Headquartered in Northfield, Ill., Medline has over 38,000 employees worldwide and operates in over 110 countries and territories.

For more information, visit


ABL Diagnostics

Chalom Sayada

General Manager

Tel.: +33 7 83 64 68 50

Medline Industries, LP

Carroll Henning

Public Relations Manager

Tel: 847-226-0587


This press release contains implicitly or explicitly certain forward-looking statements concerning ABL Diagnostics and its business. Such forward-looking statements are based on assumptions that ABL Diagnostics considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022, under number 22-296, available on the ABL Diagnostics website ( and the development of economic conditions, financial markets, and the markets in which ABL Diagnostics operates. The forward-looking statements contained in this press release are also subject to risks not yet known to ABL Diagnostics or not currently considered material by ABL Diagnostics. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of ABL Diagnostics to be materially different from such forward-looking

Share this article
Shareable URL
Prev Post

Key IT Issues Highlighted in the Global IT Experience Benchmark Report

Next Post

‘s Vyon® Porex’s Vyon® enables ReadyGo Diagnostics to begin mass production of its sample collection and preparation device

Read next